TY - JOUR
T1 - Control of cancers by combining antiangiogenesis and cancer immunotherapy
AU - Moniz, Michelle
AU - Yeatermeyer, Jessica
AU - Wu, T. C.
PY - 2005/7
Y1 - 2005/7
N2 - Ideally, cancer therapy would eliminate tumor growth at multiple sites in the body without damaging normal cells. In this regard, antiangiogenesis and immunotherapy may represent two potential approaches for control of cancers. Inhibition of tumor-specific angiogenesis restrains neoplastic growth by sequestering cancerous cells from an adequate blood supply, while activation of cancer-specific T cell-mediated immune responses can initiate attacks on tumors associated with a specific antigen. A novel approach that combines both strategies may potentially generate a better antitumor effect. In this review, we will outline the fields of cancer antiangiogenesis and cancer immunotherapy, including their advantages and limitations. In addition, we will discuss the feasibility of combining both mechanisms to generate a more powerful strategy for cancer therapy.
AB - Ideally, cancer therapy would eliminate tumor growth at multiple sites in the body without damaging normal cells. In this regard, antiangiogenesis and immunotherapy may represent two potential approaches for control of cancers. Inhibition of tumor-specific angiogenesis restrains neoplastic growth by sequestering cancerous cells from an adequate blood supply, while activation of cancer-specific T cell-mediated immune responses can initiate attacks on tumors associated with a specific antigen. A novel approach that combines both strategies may potentially generate a better antitumor effect. In this review, we will outline the fields of cancer antiangiogenesis and cancer immunotherapy, including their advantages and limitations. In addition, we will discuss the feasibility of combining both mechanisms to generate a more powerful strategy for cancer therapy.
UR - http://www.scopus.com/inward/record.url?scp=26844483805&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=26844483805&partnerID=8YFLogxK
U2 - 10.1358/dot.2005.41.7.893623
DO - 10.1358/dot.2005.41.7.893623
M3 - Review article
C2 - 16193100
AN - SCOPUS:26844483805
SN - 1699-3993
VL - 41
SP - 471
EP - 494
JO - Drugs of Today
JF - Drugs of Today
IS - 7
ER -